Acadia Pharma (ACAD) Tops Q4 EPS by 64c ; Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mail
Get Alerts ACAD Hot Sheet
Price: $21.47 --0%
Financial Fact:
Collaborative revenues: 5.27M
Today's EPS Names:
KTB, CABO, FDUS, More
Financial Fact:
Collaborative revenues: 5.27M
Today's EPS Names:
KTB, CABO, FDUS, More
Join SI Premium – FREE
Acadia Pharma (NASDAQ: ACAD) reported Q4 EPS of $0.86, $0.64 better than the analyst estimate of $0.22. Revenue for the quarter came in at $259.6 million versus the consensus estimate of $271.64 million.
GUIDANCE:
Acadia Pharma sees FY2025 revenue of $1.03-1.09 billion, versus the consensus of $1.05 billion.
For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ecovyst Inc. (ECVT) Tops Q3 EPS by 2c
- Ardent Health Partners, Inc. (ARDT) Tops Q3 EPS by 8c; offers guidance
- Sezzle Inc. (SEZL) Reports Q3 EPS of $1.37 ; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
